Biotech Values

[biomaven0]

If you notice in that first comment of mine they still seemed to be targeting RA as an indication. I think it was shortly later that they publicly focused on CLL.

Ibrutinib was discovered at Celera - guess it was the only good thing (for anyone who wasn't a patent attorney) that came out of that misbegotten venture.

Here's theoriginal licensing PR:

https://www.celera.com/celera/pr_1144679044

If I recall correctly, the HDAC drug actually had a higher royalty because it was viewed as the most promising of the bunch.

From an investment perspective, perhaps the optimal time to buy was just after the JNJ deal was announced and the stock went down a bit. RKRW (for one) went in heavy then, while others on the board here were more skeptical.

Peter